Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block Listing Return

8 Oct 2021 07:00

RNS Number : 4315O
Silence Therapeutics PLC
08 October 2021
 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

Date: 8th October 2021

 

Name of applicant:

Silence Therapeutics plc

Name of scheme:

Silence Therapeutics plc 2018 Employee Long Term Incentive Plan

Number and class of securities originally admitted

3,300,000 of 5 pence each

Date of admission

31st March 2021

Period of return:

From:

31st March 2021

To:

30th September 2021

Balance of unallotted securities under scheme(s) from previous return:

3,300,000

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

378,159

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

2,921,841

 

Name of contact:

James Douglas

Telephone number of contact:

0799 003 0716

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRMRBBTMTTMTPB
Date   Source Headline
28th Jun 20192:06 pmRNSAdditional Listing
25th Jun 201912:09 pmRNSResult of AGM
24th Jun 20191:20 pmRNSHolding(s) in Company
21st Jun 20192:36 pmRNSHolding(s) in Company
20th Jun 20191:36 pmRNSHolding(s) in Company
20th Jun 20191:00 pmRNSHolding(s) in Company
19th Jun 20199:16 amRNSHolding(s) in Company
18th Jun 20194:37 pmRNSHolding(s) in Company
18th Jun 20191:37 pmRNSHolding(s) in Company
18th Jun 201912:28 pmRNSAdditional Listing
28th May 20197:00 amRNSCollaboration with Genomics England
20th May 20194:46 pmRNSAdditional Listing
14th May 20193:00 pmRNSAdditional Listing
30th Apr 20197:00 amRNSAdditional Listing
26th Apr 20192:35 pmRNSAdditional Listing
25th Apr 20194:55 pmRNSAdditional Listing
25th Apr 20197:00 amRNSSilence Therapeutics Announces Board Changes
18th Apr 20197:00 amRNSAppointment of Chief Financial Officer
18th Apr 20197:00 amRNSSilence Therapeutics Publication of Annual Report
16th Apr 201911:00 amRNSSilence Therapeutics Announces Board Change
16th Apr 20197:00 amRNSSilence Therapeutics appoints Head of R&D and CMO
4th Apr 20199:09 amRNSHolding(s) in Company
27th Mar 20197:00 amRNSSilence Therapeutics submits CTA for SLN124
11th Mar 20197:00 amRNS2018 Preliminary Results
7th Mar 20197:00 amRNSSilence to Present at Cowen Healthcare Conference
5th Mar 20197:00 amRNSNotice of Results
4th Mar 20193:35 pmRNSHolding(s) in Company
26th Feb 20195:24 pmRNSHolding(s) in Company
1st Feb 20194:40 pmRNSSecond Price Monitoring Extn
1st Feb 20194:35 pmRNSPrice Monitoring Extension
15th Jan 20197:00 amRNSSLN124 granted Orphan Drug Designation by EMA
9th Jan 20197:00 amRNSDeparture of Chief Financial Officer
19th Dec 20187:00 amRNSSilence Therapeutics advances next RNAi medicine
18th Dec 20184:35 pmRNSPrice Monitoring Extension
10th Dec 20187:00 amRNSSettlement and License Agreement with Alnylam
12th Oct 20186:29 pmRNSErratum: Results of Placing - Withdrawn
12th Oct 20185:12 pmRNSResults of Placing
11th Oct 201810:14 amRNSPTAB Upholds Silence Patent
10th Oct 20187:00 amRNSNew divisional patent and injunction application
5th Oct 20182:16 pmRNSHolding(s) in Company
26th Sep 20187:00 amRNSSilence to Present at Healthcare Conference
21st Sep 20182:19 pmRNSAdditional Listing
11th Sep 20187:00 amRNSInterim results for six months ended 30 June 2018
30th Aug 201810:53 amRNSHolding(s) in Company
30th Aug 201810:46 amRNSHolding(s) in Company
24th Aug 20187:00 amRNSNotice of Results
20th Aug 20189:30 amRNSSilence Therapeutics Announces Board Change
7th Aug 20187:00 amRNSLitigation: patisiran EU MA imminent
17th Jul 20183:00 pmRNSDirector/PDMR Shareholding
17th Jul 20181:00 pmRNSAppoints David Horn Solomon as CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.